CSBR Champions Oncology, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 九月 11, 2026
$4.94
· % 处于52周区间
· 高于低点
· 至高点
$4.5952周低点
$8.3152周高点
市值 (MRQ)
$69M
P/E
-61.8
EPS
$-0.08
收入
$59M
CSBR 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$4.94
市值 (MRQ)
$69M
P/E
-61.8
EPS
$-0.08
收入
$59M
ROE
-30.5%
52周区间
$5–$8
CSBR 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2015年8月12日 | 1-for-12 | 反向 |
关于 Champions Oncology, Inc. - Common Stock 公司概况（来自维基百科）
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TumorGrafts
Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014.
TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.
The process
When a cancer patient undergoes surgery or biopsy, a living sample of the tumor is obtained and implanted into the mouse, creating a mouse avatar. Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. In the event the cancer progresses or recurs, Champions also banks, or stores, each successful TumorGraft for potential future patient use.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Life Sciences Tools & Services
员工214
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$59M2018-04-30 → 2026-04-30
EPS$-0.082018-04-30 → 2026-04-30
自由现金流$-5M2017-04-30 → 2026-04-30
净利率-1.9%2019-04-30 → 2026-04-30
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | CSBR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -61.85年均值 ≈23.5 | ≈23.5 | · | · | |
| P/S (TTM) | 1.15年均值 ≈1.6 | ≈1.6 | 2.7 | 低估 | |
| 市净率 (MRQ) | 17.75年均值 ≈7.7 | ≈7.7 | 1.8 | 估值过高 | |
| 股价/自由现金流 (TTM) | -11.25年均值 ≈14.8 | ≈14.8 | · | · | |
| 市现率 (TTM) | -12.45年均值 ≈3.4 | ≈3.4 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 19.05年均值 ≈19.7 | ≈19.7 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | CSBR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -1.7%5年均值 ≈-3.4% | ≈-3.4% | -108.0% | 顶尖 | |
| 息税折旧摊销前利润率 (TTM) | 0.55%5年均值 ≈-0.32% | ≈-0.32% | -108.0% | 顶尖 | |
| 税前利润率 (TTM) | -1.5%5年均值 ≈-3.3% | ≈-3.3% | -100.0% | 顶尖 | |
| 净利润率 (TTM) | -1.9%5年均值 ≈-3.4% | ≈-3.4% | -105.8% | 顶尖 | |
| ROA | -4.0%5年均值 ≈-5.1% | ≈-5.1% | -26.0% | 顶尖 | |
| ROE | -30.5%5年均值 ≈92.6% | ≈92.6% | -34.9% | 持平 | |
| ROIC | -36.6%5年均值 ≈72.5% | ≈72.5% | -38.6% | 持平 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | CSBR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 1.05年均值 ≈0.9 | ≈0.9 | 2.9 | 低流动性 | |
| Quick Ratio (速动比率) | 0.95年均值 ≈0.8 | ≈0.8 | 1.4 | 低流动性 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | CSBR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 4.4%5年均值 ≈8.1% | ≈8.1% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 3.3%5年均值 ≈8.5% | ≈8.5% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 7.7% | · | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | 102.1% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 104.7% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | CSBR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 2.05年均值 ≈1.7 | ≈1.7 | 0.4 | 顶尖 | |
| Receivables Turnover (应收账款周转率) | 4.95年均值 ≈5.7 | ≈5.7 | 5.0 | 持平 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$277.7K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-7.2%
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2027年3月31日 | 九月 10, 2026 | $-0.03 | $-0.01 | -194.1% |
| 2026年9月30日 | $-0.03 | $-0.01 | -194.1% | |
| 2026年6月30日 | $-0.05 | $-0.05 | 2.0% | |
| 2026年3月31日 | $-0.02 | $0.09 | -121.8% | |
| 2025年12月31日 | $0.02 | $0.01 | 96.1% | |
| 2025年9月30日 | $0.02 | $-0.01 | 296.1% | |
| 2025年6月30日 | $-0.07 | $-0.20 | 65.7% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Cost of Revenue | $31M | $28M | $29M | $30M | $24M | $21M | $17M | · | · | |
| R&D Expense | $9M | $7M | $10M | $12M | $9M | $7M | $6M | $5M | $4M | |
| SG&A Expense | $11M | $9M | $11M | $10M | $9M | $7M | $7M | $5M | $4M | |
| Operating Expenses | · | · | · | · | · | · | $34M | $27M | $22M | |
| Operating Income | $-1M | $5M | $-7M | $-5M | $607.0K | $366.0K | $-2M | $270.0K | $-1M | |
| Other Non-op | $211.0K | $73.0K | $48.0K | $-11.0K | $-24.0K | $71.0K | $-42.0K | $-39.0K | $-89.0K | |
| Pretax Income | $-929.0K | $5M | $-7M | $-5M | $583.0K | $437.0K | $-2M | $231.0K | $-1M | |
| Income Tax | $246.0K | $-75.0K | $-32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| EPS (Basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 | $-0.18 | $0.01 | $-0.13 | |
| EPS (Diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | |
| Shares (Basic) | 13,832,385 | 13,659,786 | 13,547,604 | 13,541,559 | 13,197,170 | 13,138,995 | 11,843,463 | 11,340,184 | 10,991,105 | |
| Shares (Diluted) | 13,832,385 | 14,266,781 | 13,547,604 | 13,541,559 | 14,159,799 | 14,573,561 | 11,843,463 | 14,096,117 | 10,991,105 | |
| EBITDA | $260.0K | $6M | $-6M | $-3M | $2M | $2M | $-978.0K | $876.0K | $-994.0K |
资产负债表
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $10M | $3M | $10M | $9M | $5M | $8M | $3M | $856.0K | |
| Receivables | $13M | $11M | $10M | $8M | $10M | $7M | $5M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | $957.0K | $385.0K | $308.0K | $287.0K | |
| Current Assets | $19M | $22M | $14M | $19M | $20M | $13M | $13M | $8M | $5M | |
| PP&E (Net) | · | · | · | · | $7M | $6M | $4M | $3M | $2M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | |
| Accum. Depreciation | $13M | $12M | $10M | $9M | $6M | $4M | $3M | $2M | $1M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $670.0K | $669.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K | $15.0K | $128.0K | $128.0K | $116.0K | |
| Total Assets | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Accounts Payable | $7M | $4M | $6M | $5M | $3M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $1M | $569.0K | |
| Current Liabilities | $20M | $24M | $22M | $22M | $17M | $11M | $12M | $8M | $7M | |
| Capital Leases | $3M | $5M | $6M | $7M | $8M | $9M | $3M | $0 | $17.0K | |
| Other Non-current Liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K | $181.0K | $178.0K | $151.0K | $151.0K | |
| Total Liabilities | $23M | $29M | $28M | $30M | $26M | $20M | $16M | $9M | $8M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $11.0K | |
| Retained Earnings | $-81M | $-80M | $-85M | $-77M | $-72M | $-73M | $-73M | $-71M | $-71M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $74.0K | $0 | · | · | $0 | $1M | |
| Stockholders' Equity | $4M | $4M | $-2M | $5M | $9M | $7M | $5M | $2M | $3.0K | |
| Liabilities + Equity | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Shares Outstanding | 13,886,826 | 13,897,503 | 13,714,099 | 13,558,650 | 13,522,441 | 13,414,066 | 12,726,728 | 11,619,538 | 11,003,228 |
现金流
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $2M | $925.0K | $825.0K | $606.0K | $360.0K | |
| Stock-based Comp | $1M | $654.0K | $1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | $431.0K | $-2M | $6M | $4M | $-4M | $3M | $492.0K | $-1M | |
| Operating Cash Flow | $-4M | $7M | $-6M | $4M | $6M | $-2M | $3M | $2M | $-1M | |
| CapEx | $564.0K | $389.0K | $836.0K | $3M | $2M | $3M | $2M | $834.0K | $1M | |
| Investing Cash Flow | $-540.0K | $-389.0K | $-836.0K | $-3M | $-2M | $-3M | $-2M | $-834.0K | $-1M | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | · | $0 | $634.0K | $74.0K | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | $-634.0K | $-74.0K | · | · | · | · | $0 | |
| Financing Cash Flow | $99.0K | $170.0K | $-527.0K | $11.0K | $207.0K | $1M | $4M | $1M | $13.0K | |
| Net Change in Cash | $-5M | $7M | $-8M | $1M | $4M | $-4M | $5M | $2M | $-2M | |
| Taxes Paid | $242.0K | $43.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M | $-5M | $685.0K | $1M | $-2M |
盈利能力
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% | 0.89% | · | 1.0% | · | |
| Net Margin | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.88% | · | 0.47% | · | |
| Pretax Margin | -1.6% | 8.1% | -14.6% | -9.8% | 1.2% | 1.1% | · | 0.85% | · | |
| EBITDA Margin | 0.44% | 10.8% | -11.3% | -5.9% | 4.3% | 3.8% | · | 3.2% | · | |
| ROA | -4.0% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -12.5% | 1.3% | -18.6% | |
| ROE | -30.5% | 211.1% | 367.4% | -91.2% | 6.0% | 4.7% | -36.9% | 5.6% | -744.4% | |
| ROIC | -36.6% | 122.7% | 384.9% | -114.8% | 6.3% | 4.1% | -36.3% | 6.7% | -46165.5% |
流动性与偿付能力
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 | |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | 1.0 | 1.1 | 0.9 | 0.6 |
效率
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.0 | 1.9 | 1.7 | 1.5 | 1.6 | 1.7 | · | 2.8 | · | |
| Receivables Turnover | 4.9 | 5.5 | 5.8 | 6.3 | 6.0 | 7.0 | · | 6.5 | · |
每股
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $0.27 | $-0.14 | $0.34 | $0.67 | $0.55 | $0.42 | $0.19 | $0.00 | |
| Revenue / Share | $4.30 | $3.99 | $3.70 | $3.98 | $3.47 | $2.82 | · | $1.92 | · | |
| Cash Flow / Share | $-0.32 | $0.52 | $-0.45 | $0.29 | $0.46 | $-0.12 | $0.25 | $0.13 | · | |
| Cash / Share | $0.35 | $0.71 | $0.19 | $0.75 | $0.67 | $0.35 | $0.65 | $0.28 | $0.08 | |
| EPS (TTM) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 |
增长率
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.4% | 13.5% | -6.9% | 9.7% | 19.7% | 27.8% | · | · | · | |
| Revenue CAGR 3Y | 3.3% | 5.1% | 6.9% | 18.8% | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.7% | 12.1% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | · | 100.0% | · | · | · | · | |
| EPS CAGR 3Y | · | 102.1% | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | · | 51.4% | · | · | · | · | |
| Net Income CAGR 3Y | · | 104.7% | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Net Income TTM | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| Market Cap | $83M | $99M | $66M | $67M | $104M | $144M | $98M | $106M | $48M | |
| P/E | -74.5 | 21.7 | -9.0 | -12.6 | 192.0 | 536.5 | -42.9 | 908.0 | -33.4 | |
| P/S | 1.4 | 1.7 | 1.3 | 1.2 | 2.1 | 3.5 | 3.1 | 36.4 | 2.4 | |
| P/B | 21.0 | 26.1 | -34.6 | 14.4 | 11.4 | 19.4 | 18.5 | 47.1 | 15918.0 | |
| P / Tangible Book | 23.0 | 28.7 | · | 15.5 | 11.9 | 20.3 | 20.6 | · | · | |
| P / Cash Flow | -18.5 | 13.3 | -10.7 | 16.8 | 16.0 | -85.6 | 33.8 | 56.7 | -39.0 | |
| P / FCF | -16.4 | 14.1 | -9.4 | 60.6 | 25.2 | -29.0 | 143.4 | 102.6 | -19.5 | |
| Earnings Yield | -1.3% | 4.6% | -11.1% | -7.9% | 0.52% | 0.19% | -2.3% | 0.11% | -3.0% |
损益表
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $14M | $17M | $15M | $14M | $12M | $17M | $13M | $14M | $14M | $12M | $12M | $13M | $13M | $13M | $14M | |
| Cost of Revenue | $8M | $7M | $9M | $7M | $8M | $7M | $7M | $7M | $7M | $7M | $8M | $7M | $8M | $7M | $8M | $7M | |
| R&D Expense | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Income | $-409.0K | $-522.0K | $-276.0K | $185.0K | $-527.0K | $-2M | $4M | $732.0K | $1M | $-272.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $7.0K | |
| Other Non-op | $-6.0K | $27.0K | $39.0K | $70.0K | $75.0K | $42.0K | $19.0K | $7.0K | $5.0K | $81.0K | $58.0K | $-105.0K | $14.0K | $-20.0K | $36.0K | $-9.0K | |
| Pretax Income | $-415.0K | $-495.0K | $-237.0K | $255.0K | $-452.0K | $-2M | $5M | $739.0K | $1M | $-191.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-2.0K | |
| Income Tax | $11.0K | $172.0K | $42.0K | $18.0K | $14.0K | $-130.0K | $23.0K | $11.0K | $21.0K | $-82.0K | $11.0K | $11.0K | $28.0K | $20.0K | $17.0K | $14.0K | |
| Net Income | $-426.0K | $-728.0K | $-279.0K | $268.0K | $-466.0K | $-2M | $4M | $728.0K | $1M | $-109.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-16.0K | |
| EPS (Basic) | $-0.03 | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.14 | $0.33 | $0.05 | $0.10 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| EPS (Diluted) | · | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.12 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| Shares (Basic) | 13,897,535 | · | 13,886,797 | 13,791,913 | 13,788,414 | · | 13,700,627 | 13,593,766 | 13,593,766 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| Shares (Diluted) | · | · | 13,886,797 | 14,457,837 | 13,788,414 | · | 14,364,904 | 14,016,953 | 14,042,379 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| EBITDA | $-95.0K | · | $65.0K | $542.0K | $-169.0K | · | $5M | $1M | $2M | · | $-2M | $-1M | $-2M | · | $-2M | $567.0K |
资产负债表
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $5M | $7M | $9M | $10M | $10M | $3M | $3M | $3M | $3M | $4M | $6M | $5M | $10M | $12M | $11M | |
| Receivables | $14M | $13M | $12M | $12M | $9M | $11M | $16M | $10M | $9M | $10M | $8M | $8M | $9M | $8M | $8M | $9M | |
| Prepaid Expense | $1M | $1M | $991.0K | $1M | $1M | $1M | $713.0K | $860.0K | $1M | $1M | $835.0K | $780.0K | $1M | $1M | $661.0K | $834.0K | |
| Current Assets | $19M | $19M | $20M | $21M | $21M | $22M | $20M | $14M | $13M | $14M | $13M | $14M | $15M | $19M | $20M | $21M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8M | |
| PP&E (Gross) | $17M | $16M | $16M | $16M | $16M | $16M | $17M | $16M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $14M | |
| Accum. Depreciation | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $9M | $7M | $7M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | |
| Other Non-current Assets | $201.0K | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $184.0K | $15.0K | $15.0K | $15.0K | |
| Total Assets | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Accounts Payable | $6M | $7M | $6M | $6M | $5M | $4M | $5M | $5M | $5M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $3M | $3M | $3M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $19M | $20M | $21M | $22M | $23M | $24M | $20M | $19M | $19M | $22M | $22M | $21M | $20M | $22M | $21M | $19M | |
| Capital Leases | $10M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | |
| Other Non-current Liabilities | $215.0K | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K | $401.0K | $439.0K | $476.0K | $514.0K | $551.0K | $588.0K | $624.0K | |
| Total Liabilities | $29M | $23M | $24M | $26M | $27M | $29M | $25M | $25M | $25M | $28M | $29M | $28M | $28M | $30M | $29M | $27M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Retained Earnings | $-81M | $-81M | $-80M | $-80M | $-80M | $-80M | $-78M | $-83M | $-83M | $-85M | $-84M | $-82M | $-80M | $-77M | $-75M | $-72M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $676.0K | $74.0K | · | · | |
| Stockholders' Equity | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $681.0K | $-332.0K | $-2M | $-2M | $93.0K | $2M | $5M | $7M | $9M | |
| Liabilities + Equity | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Shares Outstanding | 13,918,569 | 13,886,826 | 13,886,826 | 13,886,326 | 13,788,421 | 13,777,170 | 13,705,570 | 13,698,903 | 13,593,766 | 13,593,766 | 13,593,766 | 13,593,766 | 13,484,110 | 13,544,228 | 13,558,650 | 13,558,650 |
现金流
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $314.0K | $344.0K | $341.0K | $357.0K | $358.0K | $354.0K | $398.0K | $399.0K | $449.0K | $490.0K | $481.0K | $484.0K | $445.0K | $437.0K | $575.0K | $560.0K | |
| Stock-based Comp | $766.0K | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K | $263.0K | $379.0K | $53.0K | $423.0K | $208.0K | $331.0K | $119.0K | |
| Other Non-cash | $-1M | · | · | · | $470.0K | · | · | · | $-2M | · | · | · | $-2M | · | · | · | |
| Operating Cash Flow | $-492.0K | $-2M | $-1M | $-2M | $600.0K | $7M | $490.0K | $-283.0K | $311.0K | $-2M | $-919.0K | $589.0K | $-4M | $-692.0K | $2M | $3M | |
| CapEx | $55.0K | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 | $-3.0K | $18.0K | $79.0K | $668.0K | $760.0K | $754.0K | $604.0K | |
| Investing Cash Flow | $-55.0K | $-238.0K | $-14.0K | $-242.0K | $-46.0K | $-253.0K | $-42.0K | $-94.0K | $0 | $3.0K | $-18.0K | $-79.0K | $-668.0K | $-760.0K | $-754.0K | $-604.0K | |
| Stock Repurchased | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $32.0K | $602.0K | $74.0K | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $0 | · | · | · | $-602.0K | · | · | · | |
| Financing Cash Flow | $33.0K | $-19.0K | $-36.0K | $168.0K | $-14.0K | $-32.0K | $0 | $239.0K | $-37.0K | $-37.0K | $-108.0K | $134.0K | $-590.0K | $-75.0K | $0 | $86.0K | |
| Net Change in Cash | $-514.0K | $-2M | $-1M | $-2M | $540.0K | $7M | $448.0K | $-138.0K | $274.0K | $-2M | $-1M | $644.0K | $-5M | $-2M | $819.0K | $3M | |
| Free Cash Flow | $-547.0K | · | · | · | $554.0K | · | · | · | $311.0K | · | · | · | $-5M | · | · | · |
盈利能力
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2.7% | · | -1.7% | 1.2% | -3.8% | · | 26.4% | 5.4% | 9.4% | · | -21.4% | -16.9% | -20.3% | · | -19.2% | 0.05% | |
| Net Margin | -2.8% | · | -1.7% | 1.8% | -3.1% | · | 26.4% | 5.4% | 9.3% | · | -21.1% | -17.9% | -20.4% | · | -19.1% | -0.11% | |
| Pretax Margin | -2.7% | · | -1.4% | 1.7% | -3.2% | · | 26.5% | 5.5% | 9.5% | · | -21.0% | -17.8% | -20.2% | · | -19.0% | -0.01% | |
| EBITDA Margin | -0.62% | · | 0.39% | 3.6% | -1.2% | · | 28.7% | 8.4% | 12.6% | · | -17.4% | -12.7% | -16.8% | · | -14.7% | 4.0% | |
| ROA | -1.3% | · | -0.94% | 0.97% | -1.6% | · | 15.7% | 2.7% | 4.8% | · | -8.0% | -6.4% | -8.0% | · | -7.0% | -0.05% | |
| ROE | -11.5% | · | -5.7% | 11.1% | -27.5% | · | 263.6% | 188.1% | 167.2% | · | -101.1% | -44.7% | -47.1% | · | -29.9% | -0.19% | |
| ROIC | -10.8% | · | -7.6% | 4.1% | -15.5% | · | 81.8% | 105.9% | -394.0% | · | 125.8% | -2113.4% | -135.6% | · | -35.0% | 0.61% |
流动性与偿付能力
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | · | 1.0 | 1.0 | 0.9 | · | 1.0 | 0.7 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 1.0 | 1.1 | |
| Quick Ratio | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.9 | 1.1 |
效率
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Receivables Turnover | 1.3 | · | 1.2 | 1.4 | 1.5 | · | 1.4 | 1.5 | 1.6 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.7 |
每股
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | · | $0.31 | $0.30 | $0.25 | · | $0.40 | $0.05 | $-0.02 | · | $-0.15 | $0.01 | $0.14 | · | $0.52 | $0.68 | |
| Revenue / Share | · | · | $1.19 | $1.04 | $1.01 | · | $1.19 | $0.96 | $1.00 | · | $0.88 | $0.86 | $0.93 | · | $0.94 | $1.06 | |
| Cash Flow / Share | · | · | · | · | $0.04 | · | · | · | $0.02 | · | · | · | $-0.30 | · | · | · | |
| Cash / Share | $0.31 | · | $0.51 | $0.61 | $0.75 | · | $0.23 | $0.20 | $0.21 | · | $0.33 | $0.41 | $0.36 | · | $0.86 | $0.80 | |
| EPS (TTM) | $-0.08 | · | $-0.15 | $0.18 | $0.21 | · | $0.44 | $-0.06 | $-0.26 | · | $-0.72 | $-0.71 | $-0.56 | · | $-0.22 | $0.01 |
估值 (TTM)
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61M | · | $58M | $58M | $57M | · | $59M | $54M | $52M | · | $49M | $50M | $53M | · | $54M | $54M | |
| Net Income TTM | $-1M | · | $-2M | $2M | $3M | · | $6M | $-598.0K | $-3M | · | $-10M | $-10M | $-8M | · | $-3M | $108.0K | |
| Market Cap | $75M | · | $102M | $95M | $87M | · | $151M | $54M | $65M | · | $79M | $74M | $88M | · | $56M | $94M | |
| P/E | -67.0 | · | -48.7 | 37.9 | 30.1 | · | 25.0 | -65.2 | -18.4 | · | -8.1 | -7.7 | -11.6 | · | -18.7 | 694.0 | |
| P/S | 1.2 | · | 1.8 | 1.6 | 1.5 | · | 2.6 | 1.0 | 1.3 | · | 1.6 | 1.5 | 1.7 | · | 1.0 | 1.7 | |
| P/B | 19.2 | · | 23.7 | 22.7 | 24.8 | · | 27.5 | 78.7 | -196.1 | · | -38.4 | 798.1 | 46.1 | · | 7.9 | 10.3 | |
| P / Tangible Book | 21.0 | · | 25.7 | 24.7 | 27.5 | · | 29.3 | 154.8 | · | · | · | · | 55.9 | · | 8.3 | 10.6 | |
| P / Cash Flow | -151.6 | · | · | · | 145.2 | · | · | · | 209.4 | · | · | · | -22.0 | · | · | · | |
| Earnings Yield | -1.5% | · | -2.1% | 2.6% | 3.3% | · | 4.0% | -1.5% | -5.4% | · | -12.4% | -13.0% | -8.6% | · | -5.3% | 0.14% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| 收入 | $59M | $57M | $50M | $54M | $49M |
| 营业利润率 % | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% |
| 净收入 | $-1M | $5M | $-7M | $-5M | $548.0K |
| 稀释后每股收益 (EPS) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
| 指标 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| 流动比率 | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 |
| 速动比率 | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 |
| 指标 | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| 自由现金流 | $-5M | $7M | $-7M | $1M | $4M |
机构持有人 (13F) 29 家申报者 · $38.4M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
29
持有价值
$38.4M
新仓位
4
已退出持仓
2
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 4 (0 与上一季度对比) | 2 (-3 与上一季度对比) | 5 (0 与上一季度对比) | 7 (0 与上一季度对比) | +134K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
激进投资者及 5%+ 股东 9 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad Makhzoumi, Scott D. Sandell ×2 申报 | 2024年5月6日 | · | 初始申报 | · | SEC |
| Norman H. Pessin, Brian Pessin ×2 申报 | 2017年8月8日 | · | 初始申报 | 被动投资 | SEC |
| PAR Investment Partners, L.P., PAR Group, L.P., PAR Capital Management, Inc., Arthur G. Epker, III ×4 申报 | 2016年10月28日 | · | 初始申报 | · | SEC |
| Joel Ackerman ×2 申报 | 2015年3月23日 | · | 初始申报 | 被动投资 | SEC |
| Ronnie Morris ×2 申报 | 2015年3月23日 | · | 初始申报 | 被动投资 | SEC |
| Battery Ventures IX, L.P., Battery Investment Partners IX, LLC, Battery Partners IX, LLC, Battery Management Corp., Scott R. Tobin, Thomas J. Crotty, Richard D. Frisbie, Kenneth P Lawler, R. David Tabors, Roger H. Lee, Neeraj Agrawal, Michael M. Brown, Jesse Feldman ×4 申报 | 2015年3月16日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2007年5月29日 | · | 初始申报 | · | SEC |
| Manuel Hidalgo. | 2007年1月18日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2007年1月11日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 18 位内幕人士 · 7 位高管 · 11 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Robert Lawrence Brainin | CEO | 2025年7月16日 A | · | 0 | 0 | $0 |
| Ronnie Morris | CEO | 2023年3月17日 P | 858878 | 0 | 0 | $0 |
| CHAMPIONS SPORTS INC | Chairman, President and CEO | 2004年10月11日 P | 9548000 | 0 | 0 | $0 |
| Mark Schonau | Accting PEO and CFO | 2010年7月21日 A | 8526 | 0 | 0 | $0 |
| Brady Davis | President | 2023年10月9日 A | · | 0 | 0 | $0 |
| Douglas D Burkett | President | 2008年10月3日 P | · | 0 | 0 | $0 |
| David Barry Miller | Vice President, Finance | 2016年7月21日 D | · | 0 | 0 | $0 |
| Philip P. Breitfeld | 董事 | 2025年11月5日 A | 5717 | 0 | 0 | $0 |
| Daniel Newman Mendelson | 董事 | 2025年11月5日 A | 198625 | 0 | 0 | $0 |
| David Sidransky | 董事 | 2025年11月5日 A | 767043 | 0 | 0 | $0 |
| Joel Ackerman | 董事 | 2025年11月5日 A | 1056539 | 0 | 0 | $0 |
| Scott R. Tobin | 董事 | 2025年11月5日 A | 30000 | 0 | 0 | $0 |
| Abba David Poliakoff | 董事 | 2021年1月19日 M | 81274 | 0 | 0 | $0 |
| Arthur G Epker III | 董事 | 2014年10月13日 A | · | 0 | 0 | $0 |
| Ana Stancic | 董事 | 2011年7月14日 A | · | 0 | 0 | $0 |
| Michael M. Brown | 10% 所有者 | 2013年1月28日 A | 16031040 | 0 | 0 | $0 |
| James Martell | · | 2012年1月6日 G | 1784828 | 0 | 0 | $0 |
| Durwood Settles | · | 2007年1月15日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 3 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
CSBR 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 7 位分析师
买入
2 28.6%
强烈买入
4 57.1%
买入
1 14.3%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
| RPID | · | -2.8 | 19.7% | -140.3% | -107.4% | · |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | · |
交易信号 近期买入/卖出信号，包含入场价和风险/回报比
目前没有公开信号 — 没有卡片被填写，这是诚实的。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 九月 11, 2026 申报